1.Role of miR-511 in the Regulation of OATP1B1 Expression by Free Fatty Acid.
Jin Fu PENG ; Li LIU ; Cheng Xian GUO ; Shi Kun LIU ; Xiao Ping CHEN ; Li Hua HUANG ; Hong XIANG ; Zhi Jun HUANG ; Hong YUAN ; Guo Ping YANG
Biomolecules & Therapeutics 2015;23(5):400-406
MicroRNAs (miRNAs) are a family of non-coding RNA that are able to adjust the expression of many proteins, including ATP-binding cassette transporter and organic cation transporter. We sought to evaluate the effect of miR-511 on the regulation of OATP1B1 expression by free fatty acids. When using free fatty acids to stimulate Chang liver cells, we found that the expression of miR-511 increased significantly while the expression of OATP1B1 decreased. We also proved that SLCO1B1 is the target gene of miR-511 with a bioinformatics analysis and using the dual luciferase reporter assay. Furthermore, the expressions of SLCO1B1 and OATP1B1 decreased if transfecting Chang liver cells with miR-511, but did not increase when transfecting the inhibitors of miR-511 into steatosis cells. Our study indicates that miR-511 may play an important role in the regulation of OATP1B1 expression by free fatty acids.
Computational Biology
;
Fatty Acids, Nonesterified
;
Humans
;
Liver
;
Luciferases
;
MicroRNAs
;
RNA, Untranslated
2.Investigation on the Frequency and Severity of Common Adverse Reactions of Japanese Encephalitis Vaccines.
Boo Young KIM ; Dong Hyun KIM ; Hun Jae LEE ; Soo Kyung JUNG ; Xiao Shan LI ; Un Yeong GO ; Sook Kyung PARK ; Young Jin HONG
Korean Journal of Pediatric Infectious Diseases 2009;16(2):183-190
PURPOSE: To evaluate the number and severity of adverse reactions after Japanese Encephalitis (JE) vaccination in children using different vaccines (inactivated vaccine or live attenuated vaccine) and to determine the ability and safety of the vaccines to provide effective immunization for JE. METHODS: From August 2006 to February 2007, we conducted a prospective cohort study of the adverse reactions associated with JE immunization in Korea. We investigated common adverse reactions during the 4 days following immunization using telephone collaborations with four public health centers and nine pediatric clinics. RESULTS: The mean age of children receiving the inactivated vaccines and live attenuated vaccines, respectively, were 1.4 y (range: 1 to 8.5) and 1.7 y (range: 1 to 8.3). The number of children that received the inactivated vaccines was 425 (64.6%). A total of 233 (35.4%) received the live attenuated vaccines. Fourteen children (3.3%) had more than one localized adverse event with the inactivated vaccine, and six (2.6%) had more than one event with the live attenuated vaccine (P=0.607). Systemic adverse reactions occurred in 5.2% vs. 8.2%, respectively, of these groups (P=0.131). Fever was more common in the live attenuated vaccine group than in the inactivated vaccine group on the day of vaccination (P=0.026). CONCLUSIONS: The rate of adverse events in our study was even lower than that previously reported. No significant difference in outcomes between inactivated vaccine and live attenuated vaccine was found in JE-immunized children. Fever was more common in the live attenuated vaccine group than in the inactivated vaccine group on the day of vaccination.
Asian Continental Ancestry Group
;
Child
;
Cohort Studies
;
Cooperative Behavior
;
Encephalitis, Japanese
;
Fever
;
Humans
;
Immunization
;
Japanese Encephalitis Vaccines
;
Korea
;
Prospective Studies
;
Public Health
;
Telephone
;
Vaccination
;
Vaccines
;
Vaccines, Attenuated
;
Vaccines, Inactivated
3.CT-Guided Sclerotherapy for Simple Renal Cysts: Value of Ethanol Concentration Monitoring.
Jin Hong YU ; Yong DU ; Yang LI ; Han Feng YANG ; Xiao Xue XU ; Hou Jun ZHENG
Korean Journal of Radiology 2014;15(1):80-86
OBJECTIVE: The aim of our study was to evaluate the differences between sclerotherapy with and without ethanol concentration monitoring for the treatment of simple renal cysts. MATERIALS AND METHODS: Sixty-seven patients with 70 simple renal cysts were randomly assigned to two groups in a 12-month prospective controlled trial. One group (group A) was treated with computed tomography (CT)-guided sclerotherapy without ethanol concentration monitoring (33 patients with 35 cysts), whereas the other group (group B) had ethanol concentration monitoring (34 patients with 35 cysts) during the procedure. Treatment outcomes between the two groups were compared 12 months later with follow-up ultrasound examination. RESULTS: After the 12-month follow-up period, the overall success rate was 74.3% in group A and 94.3% in group B (p = 0.022). The mean cyst size before and after treatment was 8.6 +/- 2.0 cm and 2.3 +/- 2.9 cm, respectively, in group A, and 8.4 +/- 1.7 cm and 0.8 +/- 1.9 cm, respectively, in group B. The final size of the cysts in group B was significantly smaller than that in group A (p = 0.015). The likelihood of treatment with ethanol concentration monitoring being successful was approximately 16 times higher than without ethanol concentration monitoring (p = 0.026; odds ratio = 15.7; 95% confidence interval: 1.38-179.49). There were no major complications in either group. CONCLUSION: Monitoring of Hounsfield units (HU) of ethanol by CT is an effective method in the treatment of simple renal cysts with ethanol sclerotherapy. The ethanol sclerotherapy procedure can be terminated at the point of clear fluid aspiration because the HU (-190) of CT scan corresponds to it.
Adult
;
Aged
;
Aged, 80 and over
;
Cysts/radiography/*therapy
;
Drug Monitoring
;
Ethanol/*administration & dosage/analysis
;
Female
;
Humans
;
Kidney Diseases, Cystic/radiography/*therapy
;
Male
;
Middle Aged
;
Prospective Studies
;
Radiography, Interventional/methods
;
Sclerosing Solutions/*administration & dosage/analysis
;
Sclerotherapy/*methods
;
Tomography, X-Ray Computed/methods
;
Treatment Outcome
;
Young Adult
4.Efficacy and Safety of Intravenous Urapidil for Older Hypertensive Patients with Acute Heart Failure: A Multicenter Randomized Controlled Trial.
Wei YANG ; Yu Jie ZHOU ; Yan FU ; Jian QIN ; Shu QIN ; Xiao Min CHEN ; Jin Cheng GUO ; De Zhao WANG ; Hong ZHAN ; Jing LI ; Jing Yu HE ; Qi HUA
Yonsei Medical Journal 2017;58(1):105-113
PURPOSE: Urapidil is putatively effective for patients with hypertension and acute heart failure, although randomized controlled trials thereon are lacking. We investigated the efficacy and safety of intravenous urapidil relative to that of nitroglycerin in older patients with hypertension and heart failure in a randomized controlled trial. MATERIALS AND METHODS: Patients (>60 y) with hypertension and heart failure were randomly assigned to receive intravenous urapidil (n=89) or nitroglycerin (n=91) for 7 days. Hemodynamic parameters, cardiac function, and safety outcomes were compared. RESULTS: Patients in the urapidil group had significantly lower mean systolic blood pressure (110.1±6.5 mm Hg) than those given nitroglycerin (126.4±8.1 mm Hg, p=0.022), without changes in heart rate. Urapidil was associated with improved cardiac function as reflected by lower N terminal-pro B type natriuretic peptide after 7 days (3311.4±546.1 ng/mL vs. 4879.1±325.7 ng/mL, p=0.027) and improved left ventricular ejection fraction (62.2±3.4% vs. 51.0±2.4%, p=0.032). Patients given urapidil had fewer associated adverse events, specifically headache (p=0.025) and tachycardia (p=0.004). The one-month rehospitalization and all-cause mortality rates were similar. CONCLUSION: Intravenous administration of urapidil, compared with nitroglycerin, was associated with better control of blood pressure and preserved cardiac function, as well as fewer adverse events, for elderly patients with hypertension and acute heart failure.
Acute Disease
;
Aged
;
Antihypertensive Agents/*administration & dosage
;
Blood Pressure/drug effects
;
Cause of Death
;
Female
;
Heart Failure/*drug therapy/physiopathology
;
Heart Rate/drug effects/physiology
;
Hemodynamics
;
Humans
;
Hypertension/*drug therapy/physiopathology
;
Injections, Intravenous
;
Male
;
Middle Aged
;
Natriuretic Peptide, Brain/blood
;
Nitroglycerin/administration & dosage
;
Peptide Fragments/blood
;
Piperazines/*administration & dosage
;
Ventricular Function, Left/drug effects/physiology
5.Germline Mutations of BRCA1 Gene in Korean Breast and/or Ovarian Cancer Families.
Yong Jin WON ; Jae Hwan OH ; Xiao Hong HUANG ; Dong Young NOH ; Kuk Jin CHOE ; Soon Beom KANG ; Lee Su KIM ; Man Su NOH ; Nam Sun PAIK ; Dae Hyun YANG ; Se Min OH ; Soon Nam LEE ; Jae Gahb PARK
Journal of the Korean Cancer Association 1997;29(5):713-723
PURPOSE: To understand the involvement of BRCA1 gene in Korean breast and/or ovarian cancer families. MATERIALS AND METHODS: Germline mutations of BRCA1 gene were analyzed in 13 families which included 3 hereditary site-specific breast cancer families, 6 suspected breast cancer families, and 3 suspected breast-ovarian cancer family, and one Li-Fraumeni family by screening BRCA1 gene using single strand conformation polymorphism (SSCP) analysis on polymerase chain reaction (PCR) amplified genomic DNA and confirmed the results by sequencing. RESULTS: Including one family with previously reported nonsense mutation of BRCA1 gene, we detected two mutations in unrelated families. One newly identified mutation was frame shift mutation resulting from TG deletion in codon 1701, which results in a truncated BRCA1 protein, at codon 1714. CONCLUSION: The proportion of families who inherit the mutated BRCA1 gene seems to be small among Korean breast and/or ovarian cancer families.
BRCA1 Protein
;
Breast Neoplasms
;
Breast*
;
Codon
;
Codon, Nonsense
;
DNA
;
Frameshift Mutation
;
Genes, BRCA1*
;
Germ-Line Mutation*
;
Humans
;
Mass Screening
;
Ovarian Neoplasms*
;
Polymerase Chain Reaction
6.Parkinson's Disease with Fatigue: Clinical Characteristics and Potential Mechanisms Relevant to α-Synuclein Oligomer.
Li Jun ZUO ; Shu Yang YU ; Fang WANG ; Yang HU ; Ying Shan PIAO ; Yang DU ; Teng Hong LIAN ; Rui Dan WANG ; Qiu Jin YU ; Ya Jie WANG ; Xiao Min WANG ; Piu CHAN ; Sheng Di CHEN ; Yongjun WANG ; Wei ZHANG
Journal of Clinical Neurology 2016;12(2):172-180
BACKGROUND AND PURPOSE: The aim of this study was to identify the clinical characteristics and potential mechanisms relevant to pathological proteins in Parkinson's disease (PD) patients who experience fatigue. METHODS: PD patients (n=102) were evaluated using a fatigue severity scale and scales for motor and nonmotor symptoms. The levels of three pathological proteins-α-synuclein oligomer, β-amyloid (Aβ)(1-42), and tau-were measured in 102 cerebrospinal fluid (CSF) samples from these PD patients. Linear regression analyses were performed between fatigue score and the CSF levels of the above-listed pathological proteins in PD patients. RESULTS: The frequency of fatigue in the PD patients was 62.75%. The fatigue group had worse motor symptoms and anxiety, depression, and autonomic dysfunction. The CSF level of α-synuclein oligomer was higher and that of Aβ1-42 was lower in the fatigue group than in the non-fatigue group. In multiple linear regression analyses, fatigue severity was significantly and positively correlated with the α-synuclein oligomer level in the CSF of PD patients, after adjusting for confounders. CONCLUSIONS: PD patients experience a high frequency of fatigue. PD patients with fatigue have worse motor and part nonmotor symptoms. Fatigue in PD patients is associated with an increased α-synuclein oligomer level in the CSF.
Anxiety
;
Cerebrospinal Fluid
;
Depression
;
Fatigue*
;
Humans
;
Linear Models
;
Parkinson Disease*
;
Weights and Measures